HIV Prevention Shot Approved: FDA Update
- The Food and Drug Management approved lenacapavir as a long-acting injectable for HIV prevention, offering a new option with doses administered only twice a year.
- for treating adults with drug-resistant HIV, is a first-in-class capsid inhibitor.The preventative treatment involves two subcutaneous injections given approximately every six months.
- Gilead Sciences, the drug's manufacturer, announced the approval and will market lenacapavir as PrEP under the brand name Yeztugo.
The FDA has approved lenacapavir,a groundbreaking long-acting injectable,for HIV prevention,marking a significant advancement in preventative care. This new option, administered just twice a year, is a game-changer, particularly for those who find it hard to stick to daily oral medications. Lenacapavir, a first-in-class capsid inhibitor, is already authorized to treat drug-resistant HIV, highlighting its versatility. Gilead sciences will market this as PrEP under the brand name Yeztugo, News Directory 3 reports. The approval ushers in a new era in the fight against HIV transmission.The new preventative treatment only need two subcutaneous injections per every six months. Learn about what this means for the ongoing fight against HIV, adn what’s next. Discover what’s next …
FDA OKs Lenacapavir as Long-Acting PrEP for HIV prevention
The Food and Drug Management approved lenacapavir as a long-acting injectable for HIV prevention, offering a new option with doses administered only twice a year. this development significantly extends the interval between doses compared too existing preventative medications.
Lenacapavir, already approved in the U.S. for treating adults with drug-resistant HIV, is a first-in-class capsid inhibitor.The preventative treatment involves two subcutaneous injections given approximately every six months.
Gilead Sciences, the drug’s manufacturer, announced the approval and will market lenacapavir as PrEP under the brand name Yeztugo. The FDA approved it for adolescents and adults weighing at least 77 pounds. Gilead Chairman and CEO Daniel O’Day hailed the approval as ”a historic day” in the ongoing fight against HIV.
This marks the second long-acting injectable approved for HIV prevention. The first,cabotegravir,manufactured by ViiV Healthcare,was previously approved by the FDA.
What’s next
The approval of lenacapavir offers a promising new tool in the effort to prevent HIV transmission, especially for individuals who may find it challenging to adhere to daily oral medications. Broader access and implementation strategies will be crucial in maximizing the impact of this new option for HIV prevention.